EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues
Supernus Pharmaceuticals, Inc. (SUPN) had EBITDA Margin of 3.86% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$718.95M |
|
$-38.55M |
|
$74.56M |
|
$644.39M |
|
$781.24M |
|
$-62.28M |
|
$13.25M |
|
$-49.03M |
|
$-49.03M |
|
$-38.55M |
|
$-38.55M |
|
$-38.55M |
|
$-38.55M |
|
$-62.28M |
|
$27.75M |
|
56.45M |
|
56.45M |
|
$-0.68 |
|
$-0.68 |
|
| Balance Sheet Financials | |
$644.18M |
|
$10.53M |
|
$808.47M |
|
$1.45B |
|
$338.17M |
|
-- |
|
$52.76M |
|
$390.93M |
|
$1.06B |
|
$367.38M |
|
$1.06B |
|
57.46M |
|
| Cash Flow Statement Financials | |
$47.33M |
|
$4.11M |
|
$9.13M |
|
$69.33M |
|
$129.90M |
|
$60.57M |
|
$33.05M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.90 |
|
-- |
|
-- |
|
-- |
|
-- |
|
89.63% |
|
-8.66% |
|
-8.66% |
|
|
EBITDA Margin |
3.86% |
-6.82% |
|
-5.36% |
|
$45.99M |
|
-- |
|
-- |
|
-- |
|
0.49 |
|
0.91 |
|
3.83 |
|
95.34 |
|
-3.63% |
|
-10.49% |
|
-2.65% |
|
-3.63% |
|
$18.48 |
|
$0.81 |
|
$0.84 |
|